NephroDI Therapeutics, Inc.的封面图片
NephroDI Therapeutics, Inc.

NephroDI Therapeutics, Inc.

生物技术研究

Seattle，Washington 246 位关注者

LACK OF CONCENTRATION IS OUR FOCUS

关注

关于我们

NephroDI Therapeutics is a pre-clinical development stage biopharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus in children, a pediatric orphan indication. Nephrogenic Diabetes Insipidus (NDI) is a disease where patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin. Congenital NDI in the pediatric population results primarily from mutations in the type 2 vasopressin receptor, which is located on the X chromosome. Congenital NDI has a profound impact on children. Since these children can produce up to 20 L of urine per day, They must drink 20 L (80 8oz glasses) of water per day to avoid dehydration. Children who suffer multiple episodes of severe dehydration often end up with mental retardation. For more information visit www.nephrodi.com

网站
https://nephrodi.com
所属行业
生物技术研究
规模
2-10 人
总部
Seattle，Washington
类型
私人持股

地点

  • 主要

    2200 32nd Ave W

    US，Washington，Seattle，98199

    获取路线

NephroDI Therapeutics, Inc.员工

查看全部员工

动态

  • The NephroDI team joined our colleagues at the Rare & Genetic Kidney Drug Disease Drug Development Summit in Boston this week. We are coming back informed by discussion around new nephrology and renal treatment data, clinical trial successes, and regulatory best practices. Thanks to the organizers and attendees for a valuable summit filled with great content on patient input & participation, relevant examples & lessons learned, and a diverse and collaborative room of stakeholders.

    查看Josh Knackert的档案
    Josh Knackert

    Innovation & Patient Champion | Life Science, Biotech, & Pharma Advisor | Working Parent | DEI, STEM, Entrepreneurship, & Sustainability Advocate

    The past three days have been filled with collaborative discussion and community building at the Rare & Genetic Kidney Disease Drug Development Summit.? ? ? Special kudos to the conference organizers for inclusion of a lot of great content on incorporating patient voice and participation.? ? We closed out the conference with an informative discussion between André Weinstock (Alport Syndrome Foundation), Joshua Tarnoff (NephCure), and David Feldman (National Kidney Foundation).?These three patient advocates discussed building trust and sharing insights between patients and drug developers. It is inspiring to see this small but growing community bring a larger and diversifying list of potential treatments into clinical trials for rare disease kidney patients!

    • 该图片无替代文字

  • Our CEO, Rachael A Hagan, shared some of the history of NephroDI Therapeutics, Inc. with our new partners at Sound Bioventures. Read more about our work to develop our lead asset, NDI-5001, a potential therapy for X-linked Nephrogenic Diabetes Insipidus (NDI). Sincere thanks to Sound Bioventures for so eloquently sharing this history and for their meaningful partnership in effort to treat NDI!

    查看Sound Bioventures的组织主页
    Sound Bioventures

    2,483 位关注者

    NephroDI Therapeutics: A New Approach to Treating a Rare Kidney Disease We are thrilled to feature Rachael A Hagan, CEO of NephroDI Therapeutics, Inc. in a new interview on our homepage! NephroDI is developing a novel treatment for a rare kidney disorder called Nephrogenic Diabetes Insipidus (NDI). In the interview, Rachael discusses the challenges and triumphs of developing a first-in-class therapy, the importance of strong partnerships, and the company's promising future. Read the interview here: https://lnkd.in/dKtk4fw3 #NephroDI #NDI #OrphanDrug #KidneyDisease #DrugDevelopment #MedTech #VC #Healthcare

    • 该图片无替代文字

  • NephroDI Therapeutics is thrilled to announce a Series A investment from life sciences VC, Sound Bioventures. Together with a previously announced strategic corporate partnership, the capital will be used to advance NDI-500 as a potential first-in-class treatment of Congenital Nephrogenic Diabetes Insipidus (NDI). NDI-5001 is projected to enter the clinic later this year. “These children and their families are in desperate need for new and better therapies that assist in keeping them healthy,” said Rachael A Hagan, CEO of NephroDI. “We are excited that Sound Bioventures has joined NephroDI as an investor and member of the Board. The expertise that NephroDI gains via this partnership will help propel NDI-5001 during the initial clinical phase towards proof of concept. This will position the Company to rapidly enter pivotal trials in pediatric patients with this potentially first-in-class NDI therapy.” “NephroDI has sought advice and formed close relationships with other physicians that are adult and pediatric experts in NDI, and the NDI Foundation,” stated Jeff Sands, MD, Chief Medical Officer of NephroDI. “All parties share in the common goal of advancing therapeutic options for patients suffering with NDI. I am highly optimistic about the potential of NDI-5001 to improve the quality of life in this patient population, especially in children.” https://nephrodi.com/news/

相似主页

查看职位

融资

NephroDI Therapeutics, Inc. 共 2 轮

上一轮

未知

US$2,000,000.00

在 Crunchbase 上查看更多信息